GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Retained Earnings

NRXS (Neuraxis) Retained Earnings : $-53.60 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Neuraxis's retained earnings for the quarter that ended in Jun. 2024 was $-53.60 Mil.

Neuraxis's quarterly retained earnings declined from Dec. 2023 ($-48.56 Mil) to Mar. 2024 ($-50.68 Mil) and declined from Mar. 2024 ($-50.68 Mil) to Jun. 2024 ($-53.60 Mil).

Neuraxis's annual retained earnings declined from Dec. 2021 ($-29.15 Mil) to Dec. 2022 ($-33.93 Mil) and declined from Dec. 2022 ($-33.93 Mil) to Dec. 2023 ($-48.56 Mil).

Neuraxis Retained Earnings Historical Data

The historical data trend for Neuraxis's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Retained Earnings Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
-26.12 -29.15 -33.93 -48.56

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.34 -43.25 -48.56 -50.68 -53.60

Neuraxis Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Neuraxis  (AMEX:NRXS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Neuraxis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Retained Earnings
Comparable Companies
GTBP ALZN VIRI EDSA VYNE ARAV OGEN DOMH TNXP NHWK OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Website
http://www.neuraxis.com
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042